Metformin: an old therapy that deserves a new indication for the treatment of obesity.
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment. Based on the evidence, metformin has been shown to decrease the incidence of type 2 diabetes, and compares favorably to other weight-loss medications in terms of efficacy as well as safety. Thus, metformin should be considered for a treatment indication in patients with these conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Doses of metformin greater than 1500 mg are associated with the greatest weight loss.93,94”
From Obesity Management in Adults: A Review (2023) · cites this paper as [94]
In the citing paper
“In RCTs and prospective studies, oral metformin was associated with approximately 3% weight loss, and approximately 25% to 50% of participants achieve at least 5% weight loss.94”
From Obesity Management in Adults: A Review (2023) · cites this paper as [94]
In the citing paper
“Metformin’s pleiotropic effects include decreased inflammation, increased insulin and leptin sensitivity, and decreased hunger and ghrelin levels, especially with twice-daily dosing.94”
From Obesity Management in Adults: A Review (2023) · cites this paper as [94]
In the citing paper
“Metformin is frequently offered to patients with prediabetes, polycystic ovary syndrome, and overweight/obesity and to mitigate weight gain due to antipsychotic medication, although it is not FDA approved for these diagnoses.94”
From Obesity Management in Adults: A Review (2023) · cites this paper as [94]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Child abuse: Adolescent records vs. adult recall
Femina, D. D., Yeager, C. A., & Lewis, D. O. (1990) · Child Abuse & Neglect · doi:10.1016/0145-2134(90)90033-p · Cited by 8,820
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009) · Health Affairs · doi:10.1377/hlthaff.28.5.w822 · Cited by 2,957
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Research works printed but not linked: 1
- Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States, 2014. Atlanta: U.S. Department of Health and Human Services; 2014.
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Adak, T., Samadi, A., Ünal, A. Z., & Sabuncuoğlu, S. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.12.023 · Cited by 91
Off-label drugs for weight management
Hendricks, E. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s95299 · Cited by 82
“Metformin is known to induce modest weight loss in overweight patients even without glucose abnormalities and is prescribed off-label as an adjunct to weight loss.(39,40)”
Kenawy, S., Hegazy, R., Hassan, A., El-Shenawy, S., Gomaa, N., Zaki, H., & Attia, A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183565 · Cited by 74
Ma, W., Chen, J., Meng, Y., Yang, J., Cui, Q., & Zhou, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01336 · Cited by 64
Metadata
- Authors
- Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J.
- Affiliations
- Weill Cornell Medicine (US)
- Weill Cornell Medical Center (US)
- Boston University (US)
- UnitedHealth Group (United States) (US)
- Corresponding author
- Igel, L. I.
- Venue
- Current Atherosclerosis Reports
- Published
- 2016-02-18
- Volume
- 18
- Issue
- 4
- Pages
- 16-16
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- OpenAlex
- W2284555808
- Cited by
- 52
- References
- 62
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 10 · 2017: 10 · 2016: 3
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Atherosclerosis Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, obesity, weight loss, type 2 diabetes prevention, prediabetes, anti-obesity drugs, drug repurposing
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Humans, Metformin, Neoplasms, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin: an old therapy that deserves a new indication for the treatment of obesity. https://app.cochat.ai/papers/10.1007/s11883-016-0568-3
- The paper
- Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016). Metformin: an old therapy that deserves a new indication for the treatment of obesity. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-016-0568-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.